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Introduction: Discriminating between placentally-mediated fetal growth restriction and constitutionally-
small fetuses is a challenge in obstetric practice. Placental growth factor (PlGF), measurable in the
maternal circulation, may have this discriminatory capacity.
Methods: Plasma PlGF was measured in women presenting with suspected fetal growth restriction (FGR;
ultrasound fetal abdominal circumference <10th percentile for gestational age) at sites in Canada, New
Zealand and the United Kingdom. When available, placenta tissue underwent histopathological exami-
nation for lesions indicating placental dysfunction, blinded to PlGF and clinical outcome. Lesions were
evaluated according to pre-speciﬁed severity criteria and an overall severity grade was assigned (0e3,
absent to severe). Low PlGF (concentration <5th percentile for gestational age) to identify placental FGR
(severity grade 2) was assessed and compared with routine parameters for fetal assessment. For all
cases, the relationship between PlGF and the sampling-to-delivery interval was determined.
Results: Low PlGF identiﬁed placental FGR with an area under the receiver-operator characteristic curve
of 0.96 [95% CI 0.93e0.98], 98.2% [95% CI 90.5e99.9] sensitivity and 75.1% [95% CI 67.6e81.7] speciﬁcity.
Negative and positive predictive values were 99.2% [95% CI 95.4e99.9] and 58.5% [95% CI 47.9e68.6],Molecular Medicine, Faculty
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S.J. Benton et al. / Placenta 42 (2016) 1e82respectively. Low PlGF outperformed gestational age, abdominal circumference and umbilical artery
resistance index in predicting placental FGR. Very low PlGF (<12 pg/mL) was associated with shorter
sampling-to-delivery intervals than normal PlGF (13 vs. 29.5 days, P < 0.0001).
Discussion: Low PlGF identiﬁes small fetuses with signiﬁcant underlying placental pathology and is a
promising tool for antenatal discrimination of FGR from fetuses who are constitutionally-small.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Placentally-mediated fetal growth restriction (FGR) is a patho-
logical process that reduces the growth trajectory of a fetus and
increases the risk of stillbirth, preterm delivery, serious neonatal
complications and lifelong sequelae [1e3]. FGR is clinically sus-
pected when the ultrasound estimated fetal weight or fetal
abdominal circumference is below the 10th percentile for gesta-
tional age, or serial ultrasounds suggest decreasing growth velocity
[4e6]. However, many fetuses with suspected FGR are small due to
constitutional factors and are at low risk for adverse outcomes
(“small but healthy” fetuses) [4].
Antenatal discrimination of fetuses that are small due to
placental dysfunction, rather than constitutionally-small, would
improve clinical management by focusing care on fetuses that are
truly at-risk of adverse perinatal outcome, reducing surveillance
fatigue and unnecessary intervention for pregnancies with
constitutionally-small fetuses [7,8]. Placental biomarkers such as
placental growth factor (PlGF), present in the maternal circulation,
may provide an additional clinical tool for identifying placental FGR
antenatally. Pilot work by our group suggests that low circulating
levels of PlGF may characterize pregnancies complicated by FGR
associated with signiﬁcant placental pathology [9] but larger
studies are required to elucidate its clinical utility. In this study, we
assessed the ability of PlGF to antenatally identify placental FGR,
histologically conﬁrmed after birth by the presence of signiﬁcant
placental pathology. Additionally, we assessed the sampling-to-
delivery to determine if low PlGF is an indication of clinically-
important FGR, with earlier delivery reﬂecting the physician's de-
cision to deliver in response to perceived perinatal risks.
2. Materials and methods
2.1. Study design
Through the Global Pregnancy Collaboration (http://pre-empt.
cfri.ca/colaboratory), we complemented a prospectively-recruited
cohort of antenatally-suspected FGR pregnancies in Canada with
two extant cohorts from New Zealand and the United Kingdom. All
women provided written informed consent to participate in the
study.
Eligibility criteria was: antenatally-suspected FGR, deﬁned as a
fetal abdominal circumference (AC) < 10th percentile for gesta-
tional age (GA) on ultrasound by local criteria, maternal age 18e45
years with a singleton pregnancy between 20þ0‒41þ6 weeks of
gestation. Women with chronic or gestational hypertension and/or
preeclampsia [10] at enrolment, premature rupture of membranes
at enrolment or a fetus with known chromosomal and/or congen-
ital abnormalities at enrolment or conﬁrmed after delivery were
excluded. Blood samples were collected within 14 days of the ul-
trasound identiﬁcation of FGR. The study was powered to estimate
sensitivity and speciﬁcity within ±5% percentage points for the
placental pathology-based analysis. Based on our pilot data [9],
obtaining 95% sensitivity and 90% speciﬁcity (the lower 95% con-
ﬁdence interval limit of the point estimate in the pilot study) forPlGF to identify placental FGR required enrollment of 211 preg-
nancies with suspected FGR, assuming a conservative 35% rate of
placental FGR.
In Canada, womenwere recruited from inpatient and outpatient
services at BC Women's Hospital (Vancouver, H12-00504 C&W
Research Ethics Board) and the Ottawa Hospital (Ottawa, 20120660
TOH Ethics Board) between April 2012eJune 2014, extending the
published pilot study [9]. Baseline and post-enrolment data about
the women, their pregnancies and perinatal outcomes were
abstracted from medical charts after delivery. Umbilical artery
resistance index (RI) percentile was determined for GA at Doppler
examination [11]. Birthweight percentile was determined using a
Canadian national birthweight reference [12].
A cohort of FGR pregnancies from Auckland, New Zealand with
banked maternal blood samples and wax-embedded placental
tissue (NTX/11/056/02 Northern Regional Ethics Committee) was
identiﬁed through the Global Pregnancy Collaboration. Eligible
women, both inpatients and outpatients, were recruited from Na-
tional Women's Hospital for a series of antenatal studies between
1993 and 1997 [13e16]. Detailed data pertaining to these women,
their pregnancies and perinatal outcomes were collected by
research midwives after delivery and stored in a study database.
From this database, women meeting our eligibility criteria were
selected for inclusion. Umbilical artery RI percentile for GA was
determined [11]. Birthweight percentile was determined using a
New Zealand reference [17].
A cohort of FGR pregnancies from the United Kingdom with
banked maternal blood samples was identiﬁed through the Global
Pregnancy Collaboration. The PELICAN-FGR Study (East London
Research Ethics Committee, ref.10/H0701/117) [18] recruited
women presenting with reduced symphysis-fundal height between
2011 and 2013. Fetal biometry was assessed by ultrasound and a
maternal blood sample was collected during this antenatal visit.
Detailed data pertaining to these women, their pregnancies and
perinatal outcomes were collected by research midwives after de-
livery and stored in a study database. From this database, women
meeting our eligibility criteria were selected for inclusion. Birth-
weight percentile was determined using the Canadian standard as a
recent multiethnic standard [12].2.2. PlGF analysis
In all cohorts, maternal venous blood was collected by veni-
puncture using 10 mL EDTA plasma tubes. Plasma was isolated by
centrifugation at 3000 rpm for 10 min and stored at 80 C at all
centres. Samples were batch assayed for PlGF using an automated
immunoassay (Triage®, Alere, San Diego, CA, USA) [9,19,20]. The
detection range of the assay is 12e3000 pg/mL. Low PlGF was
deﬁned as a concentration <5th percentile for GA [20]. Very low
PlGF was deﬁned as a concentration <12 pg/mL. Laboratory staff
were masked to clinical and pathology data and clinicians were
masked to PlGF results. The integrity of the New Zealand samples
after prolonged storage at 80 C was conﬁrmed in a subset of
cases prior to this analysis (Supplemental Fig. S1).
Sample-to-delivery interval analysis (n=411) 
5 women withdrew aŌer consent
14 women delivered at other 
insƟtuƟons/out of province
n = 115
Canada
n = 134
New Zealand
n = 249
Suspected fetal growth restricƟon
(fetal abdominal circumference <10th percenƟle)
Normotensive women, 18-45 years of age
Singleton pregnancy, ≥20 weeks gestaƟon; 
no fetal anomalies or fetal chromosomal 
abnormaliƟes
Placental pathology-based analysis (n=213)
No placenta collected
n = 11
Placenta collected
n = 104
Placenta collected
n = 109
No placenta collected
n = 78
10 plasma samples with 
insuﬃcient volume for 
tesƟng
52 women were 
hypertensive at enrolment
n = 187
Canada
n = 115
New Zealand
n = 187
United Kingdom*
n = 109
Fig. 1. Women with suspected FGR from study cohorts in Canada, New Zealand and the United Kingdom. In all cases, women were normotensive at enrolment with no
documented signs or symptoms of preeclampsia, ruptured membranes, fetal anomalies, or fetal chromosomal abnormalities. Placentas were collected at delivery when possible
Womenwere enrolled at study centres in Vancouver and Ottawa (Canada) from 2012 to 2014. Women from Auckland (New Zealand) were identiﬁed from among those enrolled in a
previous study conducted from 1993 to 1997. Womenwere identiﬁed from the United Kingdom PELICAN-FGR Study conducted between 2011 and 2013. Placenta tissue collection at
the time of delivery was not part of the original PELICAN-FGR Study design.
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Placentas were collected at delivery (Canada and New Zealand).
Trimmed placental weight was recorded and 4e5 biopsies of
villous parenchyma (1 cm3 each) were randomly excised from the
central andmarginal regions of the placental disc. Tissuewere ﬁxed
in 4% neutral buffered formalin (Canada) or 10% neutral buffered
formalin (New Zealand), parafﬁn-embedded, sectioned (5 mm) and
stained with hematoxylin and eosin using standard protocol [21].
High-resolution digital images were taken (Aperio® ScanScope
[Canada], Metasystems® VSlide [Auckland]). Images were stored on
external hard drives for evaluation in Ottawa (Canada).
A single, experienced placental pathologist (D.G.), masked to
PlGF and clinical outcomes, examined the digital images of
placental tissue using a Placental Examination Rubric
(Supplemental Table S1) that evaluated and graded pathological
lesions of maternal malperfusion, fetal villous stromal maldevel-
opment, villitis, perivillous ﬁbrin deposition, fetal thrombotic vas-
culopathy, abruption, intraplacental hematoma and
chorioamnionitis according to pre-speciﬁed deﬁnitions based on
published guidelines [22e24]. A placental pathology grade (0e3)
was assigned to each placenta as deﬁned a priori in the Examination
Rubric. A severity grade of 2 or 3 was considered to reﬂect placental
FGR and a grade of 0 or 1 to reﬂect a constitutionally-small fetus.
For 53 of the 109 Auckland women, tissue blocks were unavai-
lable. For these cases, the placental pathology severity grade was
assigned with the Examination Rubric (by D.G.) using placental
pathology variables from the study database. These pathology
variables were collected prospectively by direct microscopy by a
single Perinatal Pathologist (by Y.C.) using pre-speciﬁed criteria
during the original study period and included placental infarction,ischaemic changes, calciﬁcation, syncytial knots, villous maturity,
ﬁbrin deposition, villitis, intraplacental hematoma and placental
abruption ranked mild, moderate or severe.
2.4. Statistics
Analyses were performed using Prism 5.0 (GraphPad, CA, USA).
P-values <0.05 were considered to indicate statistical signiﬁcance.
Normally-distributed data were reported using means with stan-
dard deviations and non-normally distributed data using medians
with interquartile ranges. Categorical variables were reported using
counts and proportions.
For the placental pathology-based analysis, the ability of low
PlGF (concentration <5th percentile for GA) to predict placental
FGR was assessed by calculating sensitivity, speciﬁcity, positive and
negative predictive values, and positive and negative likelihood
ratios with 95% conﬁdence intervals. These analyses were repeated
to include only women with blood samples collected prior to 35
weeks of gestation to account for the physiological decline of PlGF
towards term.20 Additionally, performance was assessed according
to gestational age at onset (early vs late deﬁned as <32 weeks and
32 weeks, respectively). Area under the receiver-operator char-
acteristic (AUROC) curves were calculated for prediction of
placental FGR by PlGF (as a percentile for GA at sampling) and for
comparison, GA at the time of suspected FGR, ultrasound AC
percentile, and umbilical artery RI percentile.
In all cases (with and without placental histology), the
sampling-to-delivery intervals betweenwomenwith very low PlGF
(<12 pg/mL), low PlGF (<5th percentile, 12 pg/mL) and normal
PlGF concentrations were compared. The percentage of ongoing
pregnancies for each gestational age day after sampling was plotted
Table 1
Characteristics of pregnancies with antenatally suspected growth restriction by PlGF concentration at enrolment from Canada, New Zealand and the United Kingdom included
in the placenta pathology-based analysis (n ¼ 213, placental histology at delivery) and the sample-to-delivery interval analysis (n ¼ 411).
Characteristic Placental pathology-based analyses Mean ± SD, median
[IQR] or n (%)
Sample-to-delivery interval analysis Mean ± SD,
median [IQR] or n (%)
At enrolment Low PlGF (n ¼ 94/213) Normal PlGF (n ¼ 119/213) Low PlGF
(n ¼ 157/411)
Normal PlGF (n ¼ 254/411)
Maternal age (years) 30.4 ± 5.8 28.5 ± 6.1a 29.5 ± 6.0 28.3 ± 5.9
Nulliparity 53 (56.4) 64 (53.8) 98 (62.4) 131 (51.6)a
Smoking during pregnancy 12 (12.8) 33 (27.7)a 33 (21.0) 34 (26.8)
Pre-pregnancy weight (kg) 61.5 ± 11.5 60.7 ± 14.0 60.9 ± 13.4 60.3 ± 12.3
Maternal BP (mmHg)
Systolic 113.3 ± 12.5 108.0 ± 13.0a 116.9 ± 16.2 111.2 ± 12.9b
Diastolic 68.4 ± 8.7 65.7 ± 8.6a 73.6 ± 13.5 69.9 ± 10.6b
Gestational age (weeks) 33.0 [29.8e35.0] 34.3 [32.3e36.0]a 33.3 [30.2
e35.4]
34.4 [32.4e36.0]b
After 32 weeks 54 (57.4) 93 (78.2)a 96 (61.1) 195 (76.8)b
Fetal ultrasound measurements (percentile for gestational age)
Abdominal circumference 3.0 [1.0e5.0] 4.0 [2.5e4.0]a 2.2 [1.0e5.0] 3.0 [1.5e6.4]a
Estimated fetal weight 8.0 [3.0e16.0] 11.0 [4.5e26.0]a 4.0 [1.0e7.0] 6.0 [3.0e9.0]a
Umbilical artery RIc 88.2 [68.0e95.0] (n ¼ 65) 72.2 [45.0e92.3]a (n ¼ 93) 86.9 [75.1
e94.9] (n ¼ 46)
67.8 [39.5e90.2]b (n ¼ 179)
Ultrasound to blood sampling interval (days) 1 [0e5] 0 [0e3]a 0 [0e5] 0 [0e3]a
Pregnancy Outcomes
HDP developed after enrollment 25 (26.6) 7 (5.9)b 39 (24.8) 16 (6.3)b
Pre-eclampsiad 8 (8.5) 0 (0)a 11 (7.0) 2 (0.8)a
Gestational hypertensione 17 (18.1) 7 (5.9)a 28 (17.8) 14 (5.5)b
Last ultrasound assessment prior to delivery (percentile for gestational age)
Abdominal circumference 3.0 [1.0e4.0] 6.5 [2.3e11.0]a e e
Estimated fetal weight 3.5 [2.0e8.3] 7.0 [3.0e19.0]a e e
Umbilical artery RIc 85.8 [54.2e96.3] 76.0 [45.3e90.3]a e e
Gestational age at delivery (weeks) 36.1 [33.6e37.6] 38.3 [37.3e39.1]b 36.9 [34.5
e38.1]
38.7 [37.7e40.0]b
Pre-term delivery <37 weeks 58 (61.7) 22 (18.5)b 79 (50.3) 33 (13.0)b
Birthweight (g) 1855 ± 721 2529 ± 402b 1993 ± 724 2629 ± 411b
Birthweight percentilef 2.0 [1.0e4.6] 5.0 [1.9e10.0]a 2.0 [1.0e6.1] 5.0 [2.0e11.4]b
Birthweight <3rd percentile 55 (58.5) 35 (29.4)b 87 (55.4) 72 (28.3)b
Trimmed placental weight (g) 293 ± 112 365 ± 78b e e
Induction of labour for fetal indication 35 (37.2) 57 (47.9) 54 (34.4) 99 (40.0)
Caesarean delivery for fetal indicationg 28 (29.8) 10 (8.4)b 41 (26.1) 19 (7.5)b
Stillbirth 6 (6.4) 0 (0)a 6 (3.8) 1 (0.4)a
Neonatal death 0 (0) 0 (0) 1 (0.6) 0 (0)
Neonatal outcome
APGAR <7 at 5 min 12 (12.8) 1 (0.8)b 14 (8.9) 2 (0.8)b
NICU admission >48 h 26 (27.7) 12 (10.1)a 31 (19.7) 15 (5.9)b
Placental IUGR
Pathology grade 2 or 3 55 (58.5) 1 (0.8)b e e
FGR: fetal growth restriction; HDP: hypertensive disorders of pregnancy; IQR: interquartile range; NICU: neonatal intensive care unit; PlGF: placental growth factor; RI:
resistance index.
Comparisons were performed between columns with women with low PlGF at the time of enrolment as the comparator group to women with normal PlGF concentration at
enrolment for each study analysis.
a P<0.05.
b P < 0.001.
c Umbilical artery resistance index percentile was determined for gestational age week at the time of Doppler examination [11].
d Preeclampsia was deﬁned as hypertension (blood pressure 140/90 mm Hg, on at least two occasions >4 h apart after 20 weeks gestation) and new onset proteinuria
(2 þ dipstick reading, 0.3 g/day by 24 h urine collection, or 30 mg/mmol by protein:creatinine ratio) [10].
e Gestational hypertension was deﬁned as non-proteinuric hypertension developing at 20þ0 weeks gestation [10].
f Birthweight percentiles were determined based on Canadian [12] (population-based) and New Zealand [17] (customized) birthweight references.
g Deﬁned as absent or reversed end diastolic ﬂow and/or an abnormal/non-reassuring heart rate trace during intrapartum monitoring.
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days) from sampling-to-delivery was compared between the
groups using the log-rank test.
3. Results
3.1. Placental pathology-based analysis (N ¼ 213)
In total, 213 pregnancies with suspected FGR and placental tis-
sue collected at delivery for placental pathology were included in
the study (Canada: n ¼ 104, New Zealand: n ¼ 109; Fig. 1). Of these
213 women, 94 (44.1%) had low PlGF at enrolment. Women withlow PlGF were enrolled at earlier GAs, had fetuses with smaller AC
percentiles, delivered earlier and preterm, had babies with lower
birthweight and birthweight percentile and were more likely to
develop pregnancy hypertension after enrolment compared with
women with normal PlGF (Table 1). All stillbirths occurred among
women with low PlGF. The median interval between ultrasound
identiﬁcation of fetal AC <10th percentile and blood sample
collection was 1 day [interquartile range (IQR) [0e5] for women
with low PlGF and 0 days [0e3] for women with normal PlGF
(P ¼ 0.003).
PlGF concentration by GA and placental pathology grade is
shown in Fig. 2. Of the 94 women with low PlGF at enrolment, 55
Gestational age at sampling (wk)
P
lG
F 
(p
g/
m
L)
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
10
100
1000
10000 Grade 0 (n=56)
Grade 1 (n=101)
Grade 2 (n=43)
Grade 3 (n=13)
Fig. 2. Maternal PlGF concentrations at the time of enrolment and placental pa-
thology grading in 213 pregnancies with suspected GR. PlGF concentration shown
for normotensive women with no pathology (Grade 0, n ¼ 56; black squares), mild
pathology (Grade 1, n ¼ 101; gray circles), moderate pathology (Grade 2, n ¼ 43; blue
triangles) and severe pathology (Grade 3, n ¼ 13; red squares). PlGF was below the 5th
percentile cut-off for gestational age at sampling in all cases of severe pathology. The
black arrows represent the cases that ended in stillbirth. The black dashed black line
represents the 5th percentile PlGF concentration for gestational age at sampling [20].
Table 2
Sensitivity and speciﬁcity of a low PlGF (concentration < 5th percentile for gestational age) to identify placental FGR in 213 pregnancies with antenatally suspected FGR.
Sensitivity [95% CI] Speciﬁcity [95% CI] PPV [95% CI] NPV [95% CI] þLR [95% CI] -LR [95% CI]
Enrolment at any gestational age (n ¼ 213) 98.2 [90.5e99.9] 75.1 [67.6e81.7] 58.5 [47.9e68.6] 99.2 [95.4e99.9] 3.95 [3.01e5.20] 0.024 [0.0030e0.17]
Enrolment <35 weeks gestation (n ¼ 141) 100.0 [92.3e100.0] 74.7 [64.8e83.1] 65.7 [53.4e76.7] 100.0 [95.0e100.0] 3.92 [2.77e5.54] 0.014 [0.0010e0.23]a
Enrolment <32 weeks gestation (n ¼ 66) 100.0 [89.1e100.0] 76.5 [58.9e89.3] 80.0 [64.4e91.0] 100.0 [86.8e100.0] 4.25 [2.31e7.77] 0.004 [00.10e0.32]a
Enrolment 32 weeks gestation (n ¼ 147) 95.8 [78.9e98.9] 74.8 [66.2e82.2] 42.6 [29.2e56.8] 98.9 [94.2e100.0] 3.80 [2.77e5.21] 0.056 [0.0080e0.38]
New Zealand database cases excluded (n ¼ 160) 98.0 [89.2e100.0] 71.2 [61.8e79.4] 60.0 [48.4e70.8] 98.8 [93.2e100.0] 3.40 [2.53e4.56] 0.029 [0.004e0.20]
þLR: positive likelihood ratio; -LR: negative likelihood ratio; CI: 95% conﬁdence interval; NPV: negative predictive value; PPV: positive predictive value.
a Due to lack of false positive cases, a value of 0.5 was input into the 2  2 contingency table in order to calculate the negative likelihood ratio.
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Abdominal circumference at enrolment
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Fig. 3. Area under the receiver operating characteristic curves for the prediction of
placental FGR by PlGF and other clinical parameters of fetal assessment in 213
pregnancies with antenatally suspected FGR and placental histology. PlGF
(percentile for gestational age at the time of enrolment) had an area under the curve of
0.96 (0.93e0.98) for predicting placental FGR (red line), outperforming gestational age
at enrolment [0.73 (0.65e0.81); blue line], umbilical artery resistance index percentile
at enrolment [(0.66 (0.60e0.76); green line] and abdominal circumference percentile
at enrolment [0.64 (0.54e0.73); purple line].
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woman with normal PlGF had placental FGR (P < 0.0001). All six
stillbirths showed moderate or severe placental pathology (Grade
2, n ¼ 2; Grade 3, n ¼ 4).
Low PlGF had 98.2% [95% conﬁdence interval 90.5e99.9]
sensitivity and 75.1% [67.6e81.7] speciﬁcity in identifying preg-
nancies with placental FGR as determined by placenta pathology
grade. Negative and positive predictive values were 99.2%
[95.4e99.9] and 58.5% [47.9e68.6], respectively (Table 2). Sensi-
tivity analyses excluding women enrolled35 weeks of pregnancy,
or excluding the 53 New Zealand women who had pathology
graded based on the New Zealand study database, did not alter the
results (Table 2).
Low PlGF had an AUROC of 0.96 [0.93e0.98] to predict placental
FGR. PlGF outperformed other readily-available clinical parameters
(GA, AC percentile, umbilical artery RI percentile) in predicting
placental FGR (Fig. 3).
3.2. Sampling-to-delivery interval (N ¼ 411)
In total, 411 women with suspected FGR (with and without
placental pathology; Table 1) were included in this analysis (Can-
ada: n ¼ 115, New Zealand: n ¼ 187, United Kingdom: n ¼ 109;
Fig. 1). Of these, 157 (38.2%) women had low PlGF at enrolment.
Women with low PlGF were enrolled approximately one week
earlier thanwomenwith normal PlGF and had fetuses with smallerACs, higher umbilical artery RI percentiles, delivered earlier, had
babies with lower birthweight and birthweight percentiles and
were more likely to develop pregnancy hypertension after enrol-
ment (Table 1). The median interval between ultrasound identiﬁ-
cation of fetal AC <10th percentile and blood sampling for PlGF did
not differ among women with low PlGF compared with those with
normal PlGF (0 [0e2] versus 0 [0e0], P ¼ 0.59).
Very low PlGF was associated with a shorter sampling-to-
delivery interval compared with normal PlGF (13.0 days versus
29.5 days, P < 0.0001). Sample-to-delivery intervals were signiﬁ-
cantly shorter for women with very low and low PlGF when sam-
pling occurred before 35 weeks of gestation: 14.0 days versus 33.5
versus 41.0 days, P < 0.0001 (Fig. 4).
In total, there were 7 stillbirths and one neonatal death; 6
stillbirths and the neonatal death occurred inwomenwith low PlGF
and one stillbirthwith normal PlGF. Low PlGF had 87.5% [47.4e99.7]
sensitivity and a speciﬁcity of 62.8% [57.9e67.5] to predict preg-
nancies that end in stillbirth with negative and positive predictive
values of 99.6% [97.8e100.0] and 4.7% [1.8e9.0], respectively. The
positive likelihood ratio is 2.35 [1.8e3.1] and the negative likeli-
hood ratio is 0.2 [0.03e1.2]. Thus, in this cohort, the post-test odds
of perinatal death after a low PlGF result were 4.7% and the post-
test odds after a normal PlGF were 0.4%.
Fig. 4. Percentage of ongoing pregnancies from sampling to delivery in all 411 pregnancies with antenatally suspected FGR from Vancouver and Ottawa (Canada), Auckland
(New Zealand) and the United Kingdom. Kaplan-Meier survival curves were used to plot the number of ongoing pregnancies for each day from sampling to delivery for each
group. (A) Women with very low PlGF (PlGF <12 pg/mL, n ¼ 57; black line) had shorter intervals from sampling to delivery (median: 13.0 days) than women with normal PlGF
concentrations (median: 29.5 days, P-value < 0.0001; n ¼ 254; blue line). Women with PlGF concentration <5th percentile but 12 pg/mL (n ¼ 100; red line) had a median of 29
days from sampling to delivery. (B) The interval from sampling to delivery when sampling occurred before 35 weeks gestation in women with PlGF <12 pg/mL (n ¼ 39), PlGF <5th
percentile, 12 pg/mL (n ¼ 72) and normal PlGF (n ¼ 147), respectively (14.0 days versus 33.5 days versus 41.0 days, P-value<0.0001).
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Low maternal plasma PlGF (<5th percentile for GA) identiﬁed
fetuses with placental FGR with high sensitivity (98.2%), reasonable
speciﬁcity (75.1%), high negative predictive value (99.2%) and
modest positive predictive value (58.5%). The high sensitivity, high
negative predictive value and low negative likelihood ratio (0.02)
imply that a normal PlGF concentration (5th percentile for GA)
may be a useful ‘rule-out’ test for placental FGR, particularly among
womenpresenting before 35weeks' gestation. Also, the AUC of 0.96
indicates that low PlGF appears to be more useful than available
clinical parameters, such as GA, AC or umbilical artery RI for
identifying placental FGR antenatally. Moreover, low PlGF identi-
ﬁed women destined to deliver within a shorter period of time, so
the reassurance of a normal PlGF may support expectant manage-
ment to improve neonatal outcomes.
Findings presented here support the growing body of evidence
that PlGF is a marker for placentally-mediated pregnancy compli-
cations [9,19,25e29]. PlGF is decreased in the circulation of women
with preeclampsia, with themost signiﬁcant decreases occurring in
cases of early-onset disease (<34 weeks gestation) and those
requiring delivery within 14 days of their clinical diagnosis
[19,25e29]. Studies evaluating PlGF and normotensive FGR preg-
nancies are more limited with previous reports largely using infant
birthweight percentile to deﬁne FGR [30e33]. These studies have
reported decreased PlGF in women who delivered small-for-
gestational age (SGA) neonates but poor diagnostic and/or predic-
tive performance, probably related to study populations that
included truly growth-restricted as well as constitutionally-small
fetuses [4]. Deﬁning placental FGR based on placental pathology
(conﬁrming the presence of lesions of placental dysfunction) as
opposed to size alone allows for these populations of fetuses to be
distinguished. Recently, decreased maternal PlGF was associated
with late-onset SGA fetuses with histological lesions of placental
underperfusion [34], suggesting an association between PlGF and
placental dysfunction in these pregnancies as indicated by the
presence of signiﬁcant placental pathology. Our results support
these ﬁndings as low PlGF characterised pregnancies with anoutcome of placental FGR in our study. Additionally, low PlGF may
indicate the severity of fetal compromise in placental disease. Our
sampling-to-delivery interval ﬁndings support previous studies
that suggest that low PlGF may be associated with need for early
delivery due to fetal decompensation in preeclampsia and FGR
[18,29,35]. Finally, our ﬁndings also suggest that PlGF signiﬁcantly
alters the likelihood of subsequent perinatal death, which is
consistent with the observation that stillbirths associated with FGR
exhibit a greater degree of placental abnormality than live births
with FGR [36]. Taken together, these data suggest that PlGF may be
a useful test to identify fetuses at increased risk of stillbirth
following identiﬁcation that they are small.
Major strengths of this study include the deﬁnition of
pathologically-small babies according to placental pathological
examination by a single perinatal pathologist, masked to PlGF re-
sults and clinical outcomes, as well as the use of graded placental
pathology to identify the most signiﬁcant cases. Accurate identiﬁ-
cation of placental FGR among fetuses suspected to be small is
fundamental to identifying novel tools for antenatal identiﬁcation
of fetuses at-risk. To reduce observer subjectivity, a well-
documented phenomenon associated with placental pathology
[37], we developed a Placental Examination Rubric with pre-
speciﬁed severity criteria for lesions of interest. Incorporating
lesion severity into outcome deﬁnitions allows better deﬁnition of
growth restriction of placental origin and the opportunity to better
understand the association between placental pathology and bio-
markers such as PlGF.
Limitations of our study include the temporal differences be-
tween the Canadian and New Zealand cohorts included in the
placental pathology-based analysis. The use of slightly different
criteria to deﬁne placental pathology grades in 53 pregnancies from
New Zealand may have resulted in some misclassiﬁcation. How-
ever, we believe that all signiﬁcant lesions would have been noted
by the reporting pathologist, as our sensitivity analysis excluding
the New Zealand cases without tissue available for histological
examination by the Canadian pathologist, did not alter our ﬁndings.
Additionally, our study included cases of suspected FGR presenting
over a wide range of gestational ages with a larger proportion of
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inclusion of more early-onset cases in the low PlGF groupmay have
inﬂuenced our ﬁndings as it is more often associated with placental
dysfunction. However, our sub-analysis including only late-onset
FGR cases shows that PlGF performs well as a rule-out test for
placental dysfunction (high sensitivity and NPV).
Future studies should determine how best to incorporate PlGF
testing into clinical practice in the identiﬁcation of these high-risk
pregnancies and explore the relationship with existing antenatal
surveillance tools. With an AUROC of 0.96, PlGF outperforms other
biochemical markers of placental dysfunction such as human
placental lactogen and progesterone in detecting FGR [38]. Inclu-
sion of PlGF in a predictive model for fetal compromise after
maternal perception of reduced fetal movements improved the
AUROC from 0.75 (ultrasound only) to 0.88 (ultrasound þ PlGF)
[39]. Combining PlGF with umbilical artery Doppler did not
improve the prediction of placental FGR in our study (data not
shown), suggesting that PlGF may be a more powerful marker for
placental FGR. Future studies should investigate the value of PlGF
testing with other Doppler parameters such as uterine artery,
middle cerebral artery and cerebral placental ratio indices for the
prediction of adverse outcomes in FGR pregnancies [40]. We
speculate that PlGF might be best as a rule-out test for placental
dysfunction, offering reassurance that a fetus may be
constitutionally-small and enable identiﬁcation of cases with at-
risk fetuses who warrant closer clinical surveillance (i.e. more
detailed Doppler studies). Our data advance knowledge in this ﬁeld
by suggesting that PlGF is able to discriminate fetuses with
placental disease from those who are constitutionally-small would
improve clinical management of the truly at-risk fetus and reduce
unnecessary intervention for women with pregnancies with
constitutionally-small, healthy fetuses. In our view PlGF may be a
promising tool for antenatal discrimination of growth restricted
fetuses secondary to placental disease from those who are consti-
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